Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia.
Article Details
- CitationCopy to clipboard
Meyer MD, Altenbach RJ, Basha FZ, Carroll WA, Drizin I, Elmore SW, Ehrlich PP, Lebold SA, Tietje K, Sippy KB, Wendt MD, Plata DJ, Plagge F, Buckner SA, Brune ME, Hancock AA, Kerwin JF Jr
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia.
J Med Chem. 1997 Sep 26;40(20):3141-3.
- PubMed ID
- 9379432 [ View in PubMed]
- Abstract
Not Available
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Tamsulosin Alpha-1A adrenergic receptor Ki (nM) 0.029 N/A N/A Details Tamsulosin Alpha-1B adrenergic receptor Ki (nM) 0.61 N/A N/A Details Tamsulosin Alpha-1D adrenergic receptor Ki (nM) 0.058 N/A N/A Details Terazosin Alpha-1A adrenergic receptor Ki (nM) 2 N/A N/A Details Terazosin Alpha-1B adrenergic receptor Ki (nM) 2.68 N/A N/A Details Terazosin Alpha-1D adrenergic receptor Ki (nM) 0.85 N/A N/A Details